home / stock / apre / apre news

APRE News and Press, Aprea Therapeutics Inc. From 06/17/21

Stock Information
Company Name: Aprea Therapeutics Inc.
Stock Symbol: APRE
Market: NASDAQ
Website: aprea.com
Menu
APRE APRE Quote APRE Short APRE News APRE Articles APRE Message Board
Get APRE Alerts

News, Short Squeeze, Breakout and More Instantly...
APRE - CureVac, Hecla Mining among premarket losers' pack

CureVac (CVAC) -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd (CRTD) -17% after proposing stock offeringNovan (NOVN) -14% after proposing capital raise.Torchlight Energy Resources (TRCH)&#...
APRE - Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded

3 Top Biotech Penny Stocks to Watch in 2021 Making a list of biotech penny stocks to watch is easy in 2021. With the pandemic putting a major emphasis on the biotech industry as a whole, corresponding penny stocks have jumped tremendously in value during the past year and a half. Wh...

APRE - APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aprea Therapeutics (NASDAQ: APRE ) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial for eprenetapopt, venetoclax, and azacitidine. Source: Bukhta Yurii / Shutterstock.c...

APRE - Opthea, Kindred Biosciences leads healthcare gainers; Inhibikase Therapeutics, Paratek Pharmaceuticals among major losers

Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%,...
APRE - Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, to...

APRE - Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit

BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Greg Korbel, Senior Vice President and...

APRE - Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chie...
APRE - Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three mon...

APRE - Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D D...

APRE - Shares of Aprea Therapeutics Inc. (APRE) Surpass 52-Week Low

Aprea Therapeutics Inc. (NASDAQ:APRE) traded at a new 52-week low today of $4.31. So far today approximately 1.9 million shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Aprea Therapeutics Inc. has traded in a range of $4.31 t...
Previous 10 Next 10